Evaluating Lipidated IL-22 Analogues for Obesity to Restore Metabolic Homeostasis Through a Gut-Acting Mode-of-Action for Clinically Meaningful Outcomes
- Explore how CK-0045, a first-in-class IL-22 agonist being investigated in a Phase 2a study, offers a unique approach to obesity treatment through a novel non-incretin-based mode-of-action in the gut which preserves muscle mass during weight loss
- Understand the potential of CK-0045 to be used as a standalone therapy or in combination with current standard treatments, offering a broader spectrum of benefits that address both weight loss and deeper metabolic improvements